Drug Profile
Bimatoprost periocular ring - AbbVie
Alternative Names: Bimatoprost HELIOS™ insert; Bimatoprost peri-ocular insert; Bimatoprost peri-ocular ring; Bimatoprost sustained release ocular insert; Vision-5-productLatest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator ForSight VISION5
- Developer AbbVie; Allergan
- Class Amides; Amino alcohols; Antiglaucomas; Lipids; Morpholines; Propanolamines; Prostaglandins; Small molecules; Thiadiazoles
- Mechanism of Action Prostaglandin F2alpha receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Glaucoma; Ocular hypertension
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 28 May 2019 No recent reports of development identified for phase-I development in Glaucoma in Latvia (Ophthalmic, Implant)
- 28 May 2019 No recent reports of development identified for phase-I development in Ocular-hypertension in Latvia (Ophthalmic, Implant)